摘要
目的分析乌拉地尔联合依那普利治疗高血压伴心力衰竭患者的疗效及对患者血压、心率(HR)和心功能的影响。方法选取2020年6月至2021年4月本院收治的78例高血压伴心力衰竭患者作为研究对象,按照随机数字表法分为参照组与联合组,每组39例。参照组给予依那普利治疗,联合组给予乌拉地尔联合依那普利治疗,比较两组治疗前后血压、HR、心功能和临床疗效及不良反应发生情况。结果治疗前,两组收缩压(SBP)、舒张压(DBP)水平比较差异无统计学意义;治疗后,两组SBP、DBP水平均明显低于治疗前,且联合组低于参照组,差异有统计学意义(P<0.05)。治疗前,两组HR、左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左心室射血分数(LVEF)和左心室高峰充盈率(LVPFR)比较差异无统计学意义;治疗后,两组HR均慢于治疗前,LVEDV、LVESV均小于治疗前,LVEF、LVPFR均高于治疗前,且联合组HR慢于参照组,LVEDV、LVESV均小于参照组,LVEF、LVPFR均高于参照组,差异有统计学意义(P<0.05)。联合组治疗总有效率为94.88%,明显高于参照组的74.36%,差异有统计学意义(P<0.05)。联合组不良反应发生率为7.69%,参照组为12.82%,两组比较差异无统计学意义。结论乌拉地尔联合依那普利治疗高血压伴心力衰竭疗效确切,有利于控制患者血压水平,改善其心率和心功能,且不增加不良反应,安全性较高,值得临床推广应用。
Objective To analyze the efficacy of urapidil combined with enalapril in the treatment of hypertension with heart failure and its effects on blood pressure,heart rate(HR)and cardiac function.Methods 78 patients with hypertension with heart failure treated in our hospital from June 2020 to April 2021 were selected as the research subjects,and they were divided into the reference group and the combined group according to the random number table method,with 39 cases in each group.The reference group was treated with enalapril,and the combined group was treated with urapidil combined with enalapril,the blood pressure,HR and cardiac function before and after treatment,clinical efficacy and adverse reactions were compared between the two groups.Results Before treatment,there were no statistically significant differences in the levels of systolic blood pressure(SBP)and diastolic blood pressure(DBP)between the two groups;after treatment,the levels of SBP and DBP of the two groups were lower than those before treatment,the combined group was lower than the reference group,and the differences were statistically significant(P<0.05).Before treatment,there were no significant differences in HR,left ventricular end diastolic volume(LVEDV),left ventricular end systolic volume(LVESV),left ventricular ejection fraction(LVEF)and left ventricular peak filling rate(LVPFR)between the two groups;after treatment,the HR of the two groups were slower than those before treatment,LVEDV and LVESV were lower than those before treatment,LVEF and LVPFR were higher than those before treatment,and HR in the combined group was slower than that in the reference group,LVEDV and LVESV were lower than those in the reference group,LVEF and LVPFR were higher than those in the reference group,and the differences were statistically significant(P<0.05).The total effective rate in the combined group was 94.88%,which was significantly higher than 74.36%in the reference group,and the difference was statistically significant(P<0.05).The incidence of adverse reactions in the combined group was 7.69%,and 12.82%in the reference group,and there was no significant difference between the two groups.Conclusion Urapidil combined with enalapril is effective in the treatment of hypertension with heart failure,which is conducive to control the blood pressure level of patients,improve their heart rate and cardiac function,and do not increase adverse reactions,has high safety,and is worthy of clinical promotion and application.
作者
张荣
ZHANG Rong(Department of Pharmacy,Feicheng Hospital of Shandong Guoxin Yiyang group,Feicheng,Shandong,271600,China)
出处
《当代医学》
2023年第21期52-55,共4页
Contemporary Medicine
关键词
乌拉地尔
依那普利
高血压伴心力衰竭
血压
心率
心功能
Urapidil
Enalapril
Hypertension with heart failure
Curative effect
Blood pressure
Heart rate
Cardiac function
